Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE CONTROL: Toujeo vs Standard Basal Insulin in T2DM
NCT02451137Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2015
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Toujeo Arm with Standard of Care Arm (2 arms). Primary endpoint: Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic and/or… at 6 months. Started Jun 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02451137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451137.